Physicians are cautioned that the two obstacles to reforming post-marketing clinical trials are the FDA's reluctance to revisit past approvals and its inability to enforce pharmaceutical companies' commitment to conduct Phase IV trials.
Dr Keith W. Hamilton joins Ethics Talk to discuss his article, coauthored with Dr George Maliha, Keith Robert Thomas, and Mary Ellen Nepps: “How Might Antibiotic Stewardship Programs Influence Clinicians’ Autonomy and Organizations’ Liability?”
The conventional quality-adjusted life years approach to resource allocation has greater societal value if it is distributed among many rather than concentrated on a few, assuming that severity of illness is the same.
Amy Fairchild, PhD, MPH, Ronald Bayer, PhD, and James Colgrove, PhD, MPH
A brief history of public opposition to disease surveillance in the U.S., despite the documented success of this tool in recognizing and managing threats to public health.